Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML
Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025,…
Analyst Comment
ASH 2025: golcadomide + rituximab combo shows standout potential in R/R FL
Bipolar disorder market to reach $9.4bn across 7MM by 2034
Second round of drug prices negotiated under the IRA revealed
Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
CKD-HPT, HP and HK market to reach $4bn across 7MM by 2034
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
Physicians see growing role of real-world evidence in clinical trials and beyond
